A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status:
Terminated
Trial end date:
2018-05-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on
biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in
participants with acute GvHD with lower GI involvement.